Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 platform study of Servier immunotherapy combinations in untreated PD-L1-high advanced NSCLC
2023-508730-34-00Phase 2Suspended
- Sponsor
- Servier
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of cemiplimab, S095018, sym024 and S095029 in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Servier. Primary endpoints: Incidence and severity of dose-limiting toxicities, Safety and tolerability and 2 more. Started Jul 2024; status: suspended.
02
Drugs
cemiplimabS095018sym024S095029
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-508730-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508730-34-00.